July 25, 2024 - $Edwards Lifesciences (EW.US)$shares slumped 21.39% to $68.35 in pre-market trading on Thursday. The company has reported its financial results for the quarter ended June 30, 2024 after market close on Wednesday.
Highlights and Outlook
Q2 sales grew 7%; constant currency sales grew 8%.
Q2 TAVR sales grew 5%; constant currency sales grew 6%.
Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth.
Q2 EPS of $0.61; adjusted EPS of $0.70.
Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024.
Positive EVOQUE introduction with excellent patient outcomes; NCD process on track.
Critical Care sale expected to close late Q3 2024.
Expect full-year 2024 Edwards sales growth of 8 to 10%; lowering TAVR guidance to 5 to 7% from 8 to 10%; increasing TMTT guidance to the higher end of $320 to $340 million.
![](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240725/41244218-1-5a167a7e83b38bc5fc65402824012d47.png/big)
“Second quarter total company sales growth of 8 percent reflected strong contributions from our rapidly growing TMTT product group, offset by lower-than-expected growth in TAVR," said Bernard Zovighian, CEO. “Edwards is well-positioned to deliver sustainable TAVR growth in 2025 and beyond, driven by advancements in our leading SAPIEN platform, indication expansions to much larger populations of patients, and improving patient access to this important therapy. Our vision for TMTT is becoming a reality, and our strategic commitment has developed into a growth portfolio of differentiated technologies. We are confident in Edwards' strategy in structural heart supported by the broadening TAVR opportunity, accelerating contributions of our TMTT therapies, and our expanding portfolio of structural heart innovations that addresses the unmet needs of millions of patients around the world."
Outlook
Based on current trends, the company anticipates second half TAVR sales growth similar to the first half year-over-year growth rate, or 5 to 7% full-year growth versus previous guidance of 8 to 10%. For TMTT, based on first half momentum, the company is increasing full-year sales guidance to the higher end of the previous $320 to $340 million range. The company remains confident in full-year Surgical sales growth of 6 to 8%.
The company expects Q3 sales of $1.56 to $1.64 billion, assuming Critical Care is included for the entire third quarter. The company expects EPS in Q3 of $0.67 to $0.71, assuming the inclusion of Critical Care and no impact from previously announced acquisitions. The company will provide pro forma information for Q4 2024 when third quarter results are reported, reflecting the sale of Critical Care and the acquisitions announced this month.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
2024 年 7 月 25 日- $爱德华生命科学 (EW.US)$周四盘前交易中,股价下跌21.39%,至68.35美元。该公司在周三收盘后公布了截至2024年6月30日的季度财务业绩。
亮点与展望
第二季度销售额增长了7%;固定货币销售额增长了8%。
第二季度TAVR销售额增长了5%;固定货币销售额增长了6%。
第二季度tMTT的销售额增长了75%;增加了对爱德华兹增长的贡献。
第二季度每股收益为0.61美元;调整后的每股收益为0.70美元。
重要的 TAVR 和 tMTT 临床证据将于 2024 年 10 月在 tCT 上公布。
EVOQUE 引入良好,患者疗效良好;非传染性疾病治疗步入正轨。
重症监护销售预计将于2024年第三季度末结束。
预计爱德华兹2024年全年销售额将增长8%至10%;将TAVR预期从8%下调至10%至5%至7%;将tMTT预期提高至3.2亿美元至3.4亿美元的更高水平。
首席执行官伯纳德·佐维吉安表示:“第二季度公司总销售额增长了8%,这反映了我们快速增长的tMTT产品组的强劲贡献,但被TAVR低于预期的增长所抵消。”“爱德华兹完全有能力在2025年及以后实现TAVR的可持续增长,这得益于我们领先的SAPIEN平台的进步、适应症扩展到更多患者群体以及改善患者获得这种重要疗法的机会。我们对tMTT的愿景正在成为现实,我们的战略承诺已发展成为差异化技术的增长组合。我们对爱德华兹在结构性心脏领域的战略充满信心,这得益于TAVR机会的不断扩大、我们的tMTT疗法的加速贡献以及我们不断扩大的结构性心脏创新产品组合,以满足全球数百万患者未得到满足的需求。”
外表
根据目前的趋势,该公司预计下半年TAVR的销售增长与上半年的同比增长率相似,全年增长5%至7%,而之前的预期为8%至10%。对于tMTT而言,基于上半年的势头,该公司正在将全年销售预期提高到之前的3.2亿美元至3.4亿美元区间的较高水平。该公司对全年外科销售额增长6%至8%仍然充满信心。
假设整个第三季度都包括重症监护,该公司预计第三季度销售额为15.6亿美元至16.4亿美元。该公司预计,第三季度每股收益为0.67美元至0.71美元,前提是包括重症监护,且此前宣布的收购没有影响。该公司将在公布第三季度业绩时提供2024年第四季度的预计信息,以反映重症监护的出售和本月宣布的收购。
关于爱德华兹生命科学
Edwards Lifesciences是结构性心脏病和重症监护监测领域以患者为中心的创新领域的全球领导者。我们以对患者的热情为动力,致力于通过与全球医疗保健领域的临床医生和利益相关者的合作来改善和改善生活。